BASF, Bets

BASF Bets on Catalysts and Soybeans as Investors Await November 24 Capital Markets Day

Published on 11/21/2026 at 16:12 | Editorial boerse-global.de
BASF shares closed down 2.6% at €49.45 as it ended its Evonik pursuit; Jefferies kept Underperform with a €44 target ahead of the Nov 24 capital markets day.
BASF, Bets, Catalysts, Soybeans, Investors, Await, Capital, Markets, Day, Evonik Illustration mit AI erstellt.

BASF has spent the past week stacking up announcements — a partnership, a divestment, a plant start-up and a technology upgrade — yet the share price told a different story. The stock closed Wednesday's session down 2.6% at €49.45, caught in a broad market slide that saw the STOXX 600 shed 2% as technology names sold off worldwide, according to Reuters.

The latest piece of news came midweek, when BASF and DWE agreed to work together on modular plants for renewable methanol. The division of labour is clean: DWE supplies the process engineering for the power-to-liquid route, while BASF contributes its SYNSPIRE catalysts for methanol synthesis. It is a business opportunity rather than a revenue stream at this stage, and the market treated it accordingly.

Evonik Chapter Closed, Jefferies Stays Bearish

The stock's weakness also followed BASF's decision on Thursday to end its pursuit of Evonik after the specialty chemicals group rejected two non-binding all-cash offers. RAG-Stiftung, Evonik's largest shareholder, said through dpa-AFX that it regretted the absence of deeper talks between the two management boards before BASF walked away.

Jefferies kept its "Underperform" rating on BASF with a €44 price target on Thursday, media reports indicated — a stance that underscores how skeptically at least one brokerage views the equity even as management rolls out new projects.

Should investors sell immediately? Or is it worth buying BASF?

Portfolio Reshaping: Mining Sale and a Louisiana Ramp-Up

Two portfolio moves frame the company's broader repositioning. On November 12, BASF agreed to sell its global mining solutions business to SNF, a transaction covering roughly 140 employees and the Cork production site. Completion is expected in 2027, subject to regulatory approvals.

A day earlier, the company commissioned an MDI plant at its Geismar integrated site in Louisiana, backed by an investment of around $1 billion. The new facility lifts the site's annual production capacity to roughly 600,000 tonnes.

Nemasphere: A €300 Million Peak, Not a Forecast

The project drawing the most investor attention is Nemasphere, the soybean technology BASF announced it would advance on November 16. Commercial launch in the US and Brazil is targeted for 2028, and the company puts peak sales potential at more than €300 million.

That figure describes a potential, not a forecast for the launch year and certainly not revenue already booked. The gap between launch and peak matters for valuation, and what would sharpen the picture is detail on the conditions that must be met for commercialisation in both countries and how the business could develop after the planned start.

What the Capital Markets Day Needs to Deliver

November 24 is the date investors are circling. The question is whether BASF can describe, concretely, how new projects translate into additional sales. A favourable outcome would see the company underpin the Nemasphere timeline with verifiable interim milestones, giving shareholders more than a long-term revenue opportunity — a series of checkpoints against which later progress can be measured without fully discounting the peak potential.

BASF at a turning point? This analysis reveals what investors need to know now.

For the methanol collaboration, the hurdle sits elsewhere. The agreement would gain weight if BASF could set out how concrete projects are meant to emerge from the partnership. That perspective would not be secured revenue, but it would help investors gauge the commercial value of the tie-up.

The opposite scenario is a capital markets day that emphasises potential without mapping the route to capturing it. In that case, Nemasphere's peak figure would remain an open question for valuation, and the methanol cooperation would stay a first step rather than a basis for assuming tangible proceeds.

As long as BASF holds to the planned US and Brazil launch for Nemasphere, investors have a timing anchor. Add credible interim steps and the project could carry more weight in the valuation. Push the start date back, and the prospect of first commercial sales recedes further into the future — a delay the headline peak-sales number alone would not offset.

Ad

BASF Stock: New Analysis - 21 November

Fresh BASF information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BASF analysis...

Disclaimer...
en | DE000BASF111 | BASF | boerse | 70542863 |